Prelude Therapeutics (NASDAQ:PRLD) was upgraded by analysts at
Wall Stre
Prelude Therapeutics Incorporated's (NASDAQ:PRLD) Path To Profitability [Yahoo! Finance]
Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs
PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law Firm
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Prelude Therapeutics Incorporated - PRLD